Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Inventory (2016 - 2025)

China Pharma Holdings filings provide 16 years of Inventory readings, the most recent being $2.8 million for Q4 2025.

  • On a quarterly basis, Inventory fell 2.59% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 2.59% decrease, with the full-year FY2025 number at $2.8 million, down 2.59% from a year prior.
  • Inventory hit $2.8 million in Q4 2025 for China Pharma Holdings, up from $1.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $3.9 million in Q2 2023 to a low of $1.6 million in Q3 2025.
  • Median Inventory over the past 5 years was $3.0 million (2021), compared with a mean of $3.1 million.
  • Biggest five-year swings in Inventory: skyrocketed 248.77% in 2021 and later plummeted 46.21% in 2025.
  • China Pharma Holdings' Inventory stood at $2.9 million in 2021, then changed by 0.0% to $2.9 million in 2022, then grew by 26.62% to $3.7 million in 2023, then fell by 23.91% to $2.8 million in 2024, then dropped by 2.59% to $2.8 million in 2025.
  • The last three reported values for Inventory were $2.8 million (Q4 2025), $1.6 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.